Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: Mechanistic study

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Ayadi, Amina El ^a,b   Zigmond, Michael J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; JANUS KINASE; MANGANESE SUPEROXIDE DISMUTASE; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; OXIDOPAMINE; PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; DOPAMINE; DOPAMINE TRANSPORTER; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; PROTON; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL LINE; CELL PROTECTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CELL DEATH; CELL LINE; CYTOPROTECTION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTONS; SUPEROXIDE DISMUTASE;

EID: 80053937625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024722     Document Type: Article

References (103)

1. Dirnagl U, Simon RP, Hallenbeck JM, (2003) Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26: 248-254.
2. Sommer C, (2008) Ischemic preconditioning: postischemic structural changes in the brain. J Neuropathol Exp Neurol 67: 85-92.
3. Stowe DF, Kevin LG, (2004) Cardiac preconditioning by volatile anesthetic agents: a defining role for altered mitochondrial bioenergetics. Antioxid Redox Signal 6: 439-448.
4. Tillerson JL, Cohen AD, Philhower J, Miller GW, Zigmond MJ, et al. (2001) Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21: 4427-4435.
5. Dobrossy MD, Dunnett SB, (2003) Motor training effects on recovery of function after striatal lesions and striatal grafts. Exp Neurol 184: 274-284.
6. Yu ZF, Mattson MP, (1999) Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res 57: 830-839.
7. Lee SM, Zhao H, Maier CM, Steinberg GK, (2009) The protective effect of early hypothermia on PTEN phosphorylation correlates with free radical inhibition in rat stroke. J Cereb Blood Flow Metab 29: 1589-1600.
8. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, et al. (2003) ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. Am J Physiol Heart Circ Physiol 284: H299-308.
9. Leak RK, Zigmond MJ, Liou AK, (2008) Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. J Neurochem 106: 860-874.
10. Beal MF, (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58: 495-505.
11. Zhang Y, Dawson VL, Dawson TM, (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7: 240-250.
12. Greenamyre JT, Hastings TG, (2004) Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304: 1120-1122.
13. Olanow CW, (2007) The pathogenesis of cell death in Parkinson's disease-2007. Mov Disord 22 (Suppl 17): S335-342.
14. Mattson MP, Duan W, Wan R, Guo Z, (2004) Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 1: 111-116.
15. Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, et al. (2005) Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. Neurosci Lett 373: 189-194.
16. Bezard E, Dovero S, Belin D, Duconger S, Jackson-Lewis V, et al. (2003) Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J Neurosci 23: 10999-11007.
17. Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ, (2005) Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 134: 170-179.
18. Ravati A, Ahlemeyer B, Becker A, Klumpp S, Krieglstein J, (2001) Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappaB. J Neurochem 78: 909-919.
19. Tai KK, Truong DD, (2002) Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's disease. J Neurosci Res 69: 559-566.
20. Leak RK, Liou AK, Zigmond MJ, (2006) Effect of sublethal 6-hydroxydopamine on the response to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J Neurochem 99: 1151-1163.
21. Choi HK, Won L, Roback JD, Wainer BH, Heller A, (1992) Specific modulation of dopamine expression in neuronal hybrid cells by primary cells from different brain regions. Proc Natl Acad Sci U S A 89: 8943-8947.
22. Lotharius J, O'Malley KL, (2001) Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann Neurol 49: 79-89.
23. Yamamoto BK, Bankson MG, (2005) Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit Rev Neurobiol 17: 87-117.
24. Cadet JL, Krasnova IN, Jayanthi S, Lyles J, (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202.
25. Zigmond MJ, Keefe K, (1997) 6-Hydroxydopamine as a tool for studying catecholamines in adult animals: lessons from the neostriatum; In: Kostrzewa RM, editors. Humana Press pp. 75-108.
26. Carta AR, Simola N, Morelli M, (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotoxicity Research 11: 151-167.
27. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
28. Ugarte SD, Lin E, Klann E, Zigmond MJ, Perez RG, (2003) Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J Neurosci Res 73: 105-112.
29. Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ, (2008) Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 86: 108-117.
30. Oh YJ, Wong SC, Moffat M, O'Malley KL, (1995) Overexpression of Bcl-2 attenuates MPP+, but not 6-ODHA, induced cell death in a dopaminergic neuronal cell line. Neurobiol Dis 2: 157-167.
31. Kweon GR, Marks JD, Krencik R, Leung EH, Schumacker PT, et al. (2004) Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. J Biol Chem 279: 51783-51792.
32. Ebert AD, Chen F, He X, Cryns VL, Bohn MC, (2005) A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol 191 (Suppl 1): S80-94.
33. Linsenbardt AJ, Wilken GH, Westfall TC, Macarthur H, (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30: 1030-1035.
34. Ding YM, Jaumotte JD, Signore AP, Zigmond MJ, (2004) Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 89: 776-787.
35. Imam SZ, Newport GD, Duhart HM, Islam F, Slikker W Jr, et al. (2002) Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells. Ann N Y Acad Sci 965: 204-213.
36. Warren MW, Zheng W, Kobeissy FH, Cheng Liu M, Hayes RL, et al. (2007) Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int J Neuropsychopharmacol 10: 479-489.
37. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, et al. (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. FASEB J 20: 571-573.
38. Smith KJ, Self RL, Butler TR, Mullins MM, Ghayoumi L, et al. (2007) Methamphetamine exposure antagonizes N-methyl-D-aspartate receptor-mediated neurotoxicity in organotypic hippocampal slice cultures. Brain Res 1157: 74-80.
39. Ajjimaporn A, Shavali S, Ebadi M, Govitrapong P, (2008) Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity. Brain Res Bull 77: 361-366.
40. Defazio G, Soleo L, Zefferino R, Livrea P, (1996) Manganese toxicity in serumless dissociated mesencephalic and striatal primary culture. Brain Res Bull 40: 257-262.
41. El Ayadi A, Afailal I, Errami M, (2001) Effects of voltage-sensitive calcium channel blockers on extracellular dopamine levels in rat striatum. Metab Brain Dis 16: 121-131.
42. Smith AD, Amalric M, Koob GF, Zigmond MJ, (2002) Effect of bilateral 6-hydroxydopamine lesions of the medial forebrain bundle on reaction time. Neuropsychopharmacology 26: 756-764.
43. Begum N, Ragolia L, (1996) cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem 271: 31166-31171.
44. Wall SC, Gu H, Rudnick G, (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 47: 544-550.
45. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282: 834-838.
46. Kokoshka JM, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, et al. (1998) Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res 799: 78-83.
47. Matsuzaki H, Namikawa K, Kiyama H, Mori N, Sato K, (2004) Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol Psychiatry 55: 52-60.
48. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, et al. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551.
49. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, et al. (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-588.
50. Marini M, Frabetti F, Musiani D, Franceschi C, (1996) Oxygen radicals induce stress proteins and tolerance to oxidative stress in human lymphocytes. Int J Radiat Biol 70: 337-350.
51. Carvalho F, Fernandes E, Remiao F, Gomes-Da-Silva J, Tavares MA, et al. (2001) Adaptative response of antioxidant enzymes in different areas of rat brain after repeated d-amphetamine administration. Addict Biol 6: 213-221.
52. Zuo Z, Wang Y, Huang Y, (2006) Isoflurane preconditioning protects human neuroblastoma SH-SY5Y cells against in vitro simulated ischemia-reperfusion through the activation of extracellular signal-regulated kinases pathway. Eur J Pharmacol 542: 84-91.
53. Tang XQ, Feng JQ, Chen J, Chen PX, Zhi JL, et al. (2005) Protection of oxidative preconditioning against apoptosis induced by H2O2 in PC12 cells: mechanisms via MMP, ROS, and Bcl-2. Brain Res 1057: 57-64.
54. Cadet JL, Ordonez SV, Ordonez JV, (1997) Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse 25: 176-184.
55. Chan PH, Epstein CJ, Li Y, Huang TT, Carlson E, et al. (1995) Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. J Neurotrauma 12: 815-824.
56. Behl C, (1999) Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 57: 301-323.
57. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, et al. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 60: 409-470.
58. Shankaran M, Gudelsky GA, (1998) Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol Biochem Behav 61: 361-366.
59. Abekawa T, Ohmori T, Koyama T, (1997) Tolerance to the neurotoxic effect of methamphetamine in rats behaviorally sensitized to methamphetamine or amphetamine. Brain Res 767: 34-44.
60. Johnson-Davis KL, Fleckenstein AE, Wilkins DG, (2003) The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482: 151-154.
61. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG, (2004) Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 309: 578-586.
62. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, et al. (2007) Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 559: 46-54.
63. Graham DL, Noailles PA, Cadet JL, (2008) Differential neurochemical consequences of an escalating dose-binge regimen followed by single-day multiple-dose methamphetamine challenges. J Neurochem 105: 1873-1885.
64. Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, et al. (2009) Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One 4: e7812.
65. Park SU, Ferrer JV, Javitch JA, Kuhn DM, (2002) Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J Neurosci 22: 4399-4405.
66. Kita T, Wagner GC, Nakashima T, (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92: 178-195.
67. Moroz IA, Pecina S, Schallert T, Stewart J, (2004) Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine. Exp Neurol 189: 78-93.
68. Ruffels J, Griffin M, Dickenson JM, (2004) Activation of ERK1/2, JNK and PKB by hydrogen peroxide in human SH-SY5Y neuroblastoma cells: role of ERK1/2 in H2O2-induced cell death. Eur J Pharmacol 483: 163-173.
69. Kulich SM, Chu CT, (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 77: 1058-1066.
70. Crossthwaite AJ, Hasan S, Williams RJ, (2002) Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J Neurochem 80: 24-35.
71. Stanciu M, DeFranco DB, (2002) Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem 277: 4010-4017.
72. Roux PP, Blenis J, (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344.
73. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, et al. (2004) Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 64: 5291-5300.
74. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME, (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
75. Li RC, Ping P, Zhang J, Wead WB, Cao X, et al. (2000) PKCepsilon modulates NF-kappaB and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol Heart Circ Physiol 279: H1679-1689.
76. Mockridge JW, Punn A, Latchman DS, Marber MS, Heads RJ, (2000) PKC-dependent delayed metabolic preconditioning is independent of transient MAPK activation. Am J Physiol Heart Circ Physiol 279: H492-501.
77. Mocanu MM, Bell RM, Yellon DM, (2002) PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34: 661-668.
78. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM, (2005) Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-976.
79. Hausenloy DJ, Yellon DM, (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70: 240-253.
80. Tong H, Chen W, Steenbergen C, Murphy E, (2000) Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87: 309-315.
81. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM, (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54: 2360-2364.
82. Belcheva MM, Coscia CJ, (2002) Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals 11: 34-44.
83. Lin A, Dibling B, (2002) The true face of JNK activation in apoptosis. Aging Cell 1: 112-116.
84. Saporito MS, Hudkins RL, Maroney AC, (2002) Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem 40: 23-62.
85. Peng J, Andersen JK, (2003) The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life 55: 267-271.
86. Haq SE, Clerk A, Sugden PH, (1998) Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart. FEBS Lett 434: 305-308.
87. Sato M, Cordis GA, Maulik N, Das DK, (2000) SAPKs regulation of ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H901-907.
88. Hoshida S, Yamashita N, Otsu K, Hori M, (2002) The importance of manganese superoxide dismutase in delayed preconditioning: involvement of reactive oxygen species and cytokines. Cardiovasc Res 55: 495-505.
89. De Miglio MR, Pascale RM, Simile MM, Muroni MR, Calvisi DF, et al. (2002) Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis. Cancer Res 62: 4459-4463.
90. Feng H, Xiang H, Mao YW, Wang J, Liu JP, et al. (2004) Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes. Oncogene 23: 7310-7321.
91. Berman SB, Zigmond MJ, Hastings TG, (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 67: 593-600.
92. Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE, (1998) Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences? Ann N Y Acad Sci 844: 103-107.
93. Sukhodub A, Jovanovic S, Du Q, Budas G, Clelland AK, et al. (2007) AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels. J Cell Physiol 210: 224-236.
94. Park KM, Kramers C, Vayssier-Taussat M, Chen A, Bonventre JV, (2002) Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem 277: 2040-2049.
95. Zhang QG, Wang RM, Han D, Yang LC, Li J, et al. (2009) Preconditioning neuroprotection in global cerebral ischemia involves NMDA receptor-mediated ERK-JNK3 crosstalk. Neurosci Res 63: 205-212.
96. Liu J, Wang J, Huang Q, Higdon J, Magdaleno S, et al. (2006) Gene expression profiles of mouse retinas during the second and third postnatal weeks. Brain Res 1098: 113-125.
97. Luo W, Wang Y, Reiser G, (2007) Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 56: 331-345.
98. Donovan FM, Cunningham DD, (1998) Signaling pathways involved in thrombin-induced cell protection. J Biol Chem 273: 12746-12752.
99. Cannon JR, Keep RF, Schallert T, Hua Y, Richardson RJ, et al. (2006) Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease. Brain Res 1116: 177-186.
100. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, et al. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185: 615-623.
101. Pike CJ, Vaughan PJ, Cunningham DD, Cotman CW, (1996) Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. J Neurochem 66: 1374-1382.
102. Sokolova E, Reiser G, (2008) Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost 100: 576-581.
103. Guilarte TR, (2001) Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22: 725-731.